+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Studies of multiroute exposure/dose reconstruction using physiologically based pharmacokinetic models



Studies of multiroute exposure/dose reconstruction using physiologically based pharmacokinetic models



Toxicology and Industrial Health 12(2): 153-163




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047461235

Download citation: RISBibTeXText

PMID: 8794529


Related references

Physiologically based pharmacokinetic modeling of the pregnant rat a multiroute exposure model for trichloroethylene and its metabolite trichloroacetic acid. Toxicology & Applied Pharmacology 99(3): 395-414, 1989

Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup a multiroute exposure model for trichloroethylene and its metabolite trichloroacetic acid. Toxicology & Applied Pharmacology 102(3): 497-513, 1990

Development of a multiroute physiologically based pharmacokinetic model for orbifloxacin in rabbits. Journal of Veterinary Pharmacology and Therapeutics 41(4): 622-631, 2018

Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. Journal of Pharmaceutical Sciences 104(1): 233-243, 2015

Use of a multiple pathway and multiroute physiologically based pharmacokinetic model for predicting organophosphorus pesticide toxicity. Biomarkers for agrochemicals and toxic substances: applications and risk assessment 228, 1996

Physiologically based pharmacokinetic models for dose assessment. Abstracts of Papers American Chemical Society 203(1-3): CHAS22, 1992

Physiologically-based pharmacokinetic models in risk and exposure assessment. Annali Dell'istituto Superiore di Sanita 27(4): 601-608, 1991

Physiologically based pharmacokinetic models examples of their use in exposure and risk assessment. Abstracts of Papers American Chemical Society 204(1-2): AGRO 162, 1992

Use of physiologically based pharmacokinetic models to establish biological exposure indexes. American Industrial Hygiene Association Journal 53(6): 369-374, 1992

Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose. Journal of Toxicology and Environmental Health. Part A 68(11-12): 927-950, 2005

Use of physiologically based pharmacokinetic models as adjuncts to monitoring in dose and risk assessment. Abstracts of Papers American Chemical Society 214(1-2): ENVR 85, 1997

Exposure-integrated physiologically based pharmacokinetic models for risk assessment of environmental carcinogens. Toxicology 47(1-2): 206-0, 1987

Exposure integrated physiologically based pharmacokinetic models for risk assessment of environmental carcinogens. Toxicology 47(1-2): 206, 1987

A tissue dose-based comparative exposure assessment of manganese using physiologically based pharmacokinetic modeling-The importance of homeostatic control for an essential metal. Toxicology and Applied Pharmacology 322: 27-40, 2017

Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone. Regulatory Toxicology and Pharmacology 76: 102-112, 2016